Current Issue : April-June Volume : 2026 Issue Number : 2 Articles : 5 Articles
The demand for full-range visual quality in refractive cataract surgery has driven the development of non-diffractive extended depth of focus (EDOF) intraocular lenses (IOLs). Vivity achieves depth of focus extension through the X-WaveTM wavefront shaping technology (a 2.2 mm central dual smooth surface transition element). Its hydrophobic acrylate material reduces the incidence of posterior capsule opacification (PCO) and filters harmful blue light, while the modified L-haptic design ensures capsular bag centration. Clinical data shows that in both the cataract cohort and the refractive lens exchange (RLE) cohort with bilateral Vivity implantation, the uncorrected distance visual acuity (UDVA) and uncorrected intermediate visual acuity (UIVA) are excellent, while the uncorrected near visual acuity (UNVA) is adequate for daily needs. The spectacle independence rates for distance, intermediate, and near vision were 87.9%/86.6%, 77.6%/79.3%, and 46.1%/59.8% (cataract/RLE cohorts), respectively. Additionally, 91.8%/84.1% of patients reported no visual disturbances, and the satisfaction rate exceeded 85%. Clinical comparisons indicate that Vivity exhibits optical quality close to that of monofocal IOLs, a longer depth of focus than monofocal IOLs, fewer visual disturbances than diffractive multifocal IOLs, a relatively wide depth of focus range, and excellent resistance to tilt and decentration. However, Vivity has limitations, including insufficient fine near vision (most patients require low-power near vision add-ons), significant pupil dependence, and a lack of long-term data beyond 3 years. Strategies to optimize its application include adopting a micromonovision design to improve near vision and adapting it for patients with mild epiretinal membranes and early age-related macular degeneration (AMD). Conclusion: Vivity is a recommended option for patients who require distance and intermediate vision and cannot tolerate optical disturbances from diffractive IOLs. However, in clinical practice, precise selection based on ocular parameters and visual needs is essential....
Background/Objectives: Evaluate outcomes and treatment patterns with 2 mg intravitreal aflibercept injection among patients who completed the phase 3 PANORAMA trial and enrolled in the VOYAGE (ClinicalTrials.gov identifier, NCT04708145; 12 January 2021) long-term extension study. Methods: During VOYAGE, patients were evaluated every 16 weeks and treated with 2 mg intravitreal aflibercept injection as needed depending on ophthalmoscopic examination findings. Those with no history of panretinal photocoagulation (PRP) received aflibercept if their clinician-determined diabetic retinopathy severity scale (DRSS) level was ≥47. Patients with a history of PRP received aflibercept if active neovascularization was present. New or worsening diabetic retinopathy (DR) severity prompted more frequent treatment. Results: 320 patients (1 eye per patient) from 87 sites completed the PANORAMA trial. Of these, 41 patients (13% of PANORAMA completers) from 14 sites (16%) enrolled in VOYAGE after a mean interim period of 33.7 months, and 35 patients (85%) completed study visits through 1 year. At year 1 in VOYAGE, the mean number of anti-vascular endothelial growth factor (VEGF) injections increased from 1.1 per year during the interim period to 3.4 per year and was associated with stabilization or improvement in DRSS level in 81% (26/32) of patients. Mean best-corrected visual acuity (BCVA) remained relatively stable, and mean central subfield thickness (CST) improved by 24.4 μm to 269.5 μm through year 1 of VOYAGE. There were no unexpected safety events. Conclusions: Following a mean of 3 years of routine clinical care with associated declines in DRSS level, CST, and BCVA, stabilization of DRSS level and BCVA with reductions in CST was achieved through year 1 of the VOYAGE extension study, with a concurrent increase in aflibercept dosing frequency....
Late-onset Fuchs endothelial corneal dystrophy (FECD) is a hereditary, progressive, bilateral and irreversible disorder that is characterized by thickening of Descemet’s membrane, microscopic collagenous protuberances known as guttae, and accelerated loss of corneal endothelial cells. Patients initially complain of blurred vision, and as the disease progresses, painful epithelial edema develops. Untreated cases of FECD often result in blindness, and then, the only treatment is corneal transplantation. DNA polymorphisms in many genes have been implicated, among them TCF4 on chromosome 18q, encoding a transcription factor protein E2-2, which is involved in regulating cellular growth and differentiation in the cornea. In our previous published study, we confirmed the association of an intronic TCF4 SNP (rs613872) with the disease in our population. The purpose of this present study is to further investigate another intronic point of interest in the same gene, the CTG18.1 trinucleotide repeat expansion. DNA was isolated from EDTA blood from a wellascertained group of 36 Greek patients with FECD (Krachmer scale ≥ 2) and 58 healthy individuals, age- and sex-matched after obtaining their informed consent. STR-PCR and triplet-repeat primed PCR (TP-PCR) were performed, followed by gel electrophoresis and fragment analysis on an ABI SeqStudio genetic analyzer. Our real-time qPCR genotyping method was used for the SNP in the LightCycler (Roche). Statistical analysis of both genetic results was performed with SPSS and SNPStats....
Glaucoma is a progressive optic neuropathy, often associated with hypertonia, and is the second leading cause of blindness worldwide [1]. The prevalence of glaucoma varies according to ethnic origin, being more frequent in subjects of African or Afro-Caribbean origin [2]. The aim of the study is to understand patients’ care-seeking behavior and to analyze the underlying reasons. This is a descriptive cross-sectional study conducted over a six-month period, including patients aged 30 and over diagnosed with GPAO. The results show that the most common age group was 60 - 70 years, and that 54.91% of patients did not attend any other center apart from IOTA. Satisfaction with the care received was mixed, with 52.73% of patients satisfied. Decreased visual acuity was the most frequent reason for consultation, and IOTA’s technical facilities were the most frequently cited reason for choosing this center Although limited by its strictly hospital-based nature, the study reveals patients’ behavior and reflexes when faced with the first symptoms of their disease....
Background: Thyroid eye disease (TED), or Graves’ orbitopathy, is the most common extra-thyroidal manifestation of Graves’ disease, but it has only rarely been reported after SARS-CoV-2 vaccination. Autoimmune thyroid disease, including subacute thyroiditis and Graves’ disease, has been described following COVID-19 vaccination; we present a case series of TED occurring shortly after different COVID-19 vaccines to provide clinical data on this potential safety signal. Case presentation: We describe five women (mean age 47 years; range 27–69) who developed TED 3–20 days after COVID-19 vaccination with mRNA or adenoviral vector vaccines, three of whom had pre-existing thyroid disease. Presentations included ocular and retro-orbital pain, exophthalmos, headache, goiter, tremor, depressive symptoms, and, in one case, anterior neck pain and fever. TED severity (ETA/EUGOGO) ranged from mild to severe, with frequent findings of suppressed TSH, elevated thyroid autoantibodies, and inflammatory markers, as well as imaging evidence of exophthalmos, extraocular muscle enlargement, and diffuse or multinodular goiter. Management with intravenous corticosteroids, selenium, levothyroxine adjustment, and/or intramuscular corticosteroids led to improvement in thyroid function and inflammation by 3 months, although mild TED often persisted. Conclusions: This case series supports a temporal association between COVID-19 vaccination and new-onset or exacerbated TED in individuals with autoimmune thyroid disease. Although vaccination benefits outweigh potential risks, clinicians should remain alert to ocular and thyroid symptoms after immunization to ensure timely diagnosis and management....
Loading....